In this interview we speak to José Javier García from Pivotal about his company´s involvement in a large-scale clinical trial testing the safety and efficacy of hyperimmune convalescent plasma treatment in COVID-19 patients.
Browsing: Basic > Immunology
Researchers at the Emory Vaccine Center have demonstrated that a novel adjuvant, 3M-052, can aid long-lasting immunity against HIV in rhesus monkeys. This could have implications for developing successful vaccines against HIV, influenza and COVID-19.
Take a look behind the scenes of a recent Future Virology paper, titled ‘Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: Let the…
Researchers at Scripps Research Institute have used the blood of recovered COVID-19 patients to identify potent antibodies that protect against SARS-CoV-2. The study, published in Science, has shown the antibodies’ successful use in animal models and human cell cultures.
Researchers have repurposed cancer immunotherapy tools to identify regions of SARS-CoV-2 to target with a vaccine. They believe the use of this strategy could help develop a vaccine that provides long-term protection from COVID-19.
The largest trial to date assessing the use of convalescent plasma therapy for COVID-19 has revealed that the treatment is effective in 76% of patients, with no adverse effects. Further research is needed to evaluate how to optimize this therapy.
Researchers have demonstrated that two COVID-19 vaccine candidates can protect against COVID-19 in primates, with re-exposure triggering an immune response in rhesus macaques.
After analyzing data from SARS survivors, a team of researchers from across the globe has identified an antibody that can inhibit related coronaviruses, including SARS-CoV-2. The antibody, termed S309, is now on an accelerated path towards clinical trials.
An exploratory study testing interferon α-2b treatment for COVID-19 has demonstrated improved viral clearance in a small cohort of patients. The researchers also observed a reduction in levels of inflammatory proteins in COVID-19 patients after treatment.
Building on their previous research into SARS-CoV, researchers have identified a human monoclonal antibody capable of preventing both SARS-CoV and SARS-CoV-2 from infecting cultured cells. This cross-neutralizing feature could potentially mitigate future related coronaviruses.